Indo-Bangla Pharmaceuticals (DHA:IBP) Accounts Receivable: BDT0.00 Mil (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:IBP Indo-Bangla Pharmaceuticals Ltd DHA:IBP
32 GF Score
Price BDT19.40
View Full Analysis

What is Indo-Bangla Pharmaceuticals Accounts Receivable?

Indo-Bangla Pharmaceuticals DHA:IBP 32 Accounts Receivable is BDT0.00 Mil as of . 20. GuruFocus rates DHA:IBP with a GF Score™ of 32/100.

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Indo-Bangla Pharmaceuticals's accounts receivables for the quarter that ended in . 20 was BDT0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Indo-Bangla Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in . 20 was BDTN/A.


Indo-Bangla Pharmaceuticals Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Indo-Bangla Pharmaceuticals's Days Sales Outstanding for the quarter that ended in . 20 is calculated as:

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Indo-Bangla Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Indo-Bangla Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in . 20 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(+0.75 * +0.5 * -N/A
--)/0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


Indo-Bangla Pharmaceuticals Accounts Receivable Related Terms


Indo-Bangla Pharmaceuticals Accounts Receivable Historical Data

* Premium members only.

The historical data trend for Indo-Bangla Pharmaceuticals's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Indo-Bangla Pharmaceuticals Accounts Receivable Chart

Indo-Bangla Pharmaceuticals Annual Data
Trend
Accounts Receivable

Indo-Bangla Pharmaceuticals Semi-Annual Data
Accounts Receivable
DHA:IBP
32GF Score
Indo-Bangla Pharmaceuticals Ltd DHA:IBP
Accounts Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Indo-Bangla Pharmaceuticals Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Frequently Asked Questions Learn more about Accounts Receivable →
What does a Accounts Receivable of BDT0.00 Mil mean?
Indo-Bangla Pharmaceuticals (DHA:IBP) has a Accounts Receivable of BDT0.00 Mil as of . 20. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Indo-Bangla Pharmaceuticals and its competitors.
Is Indo-Bangla Pharmaceuticals' Accounts Receivable too high?
Indo-Bangla Pharmaceuticals' current Accounts Receivable is BDT0.00 Mil. Overall, Indo-Bangla Pharmaceuticals has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Indo-Bangla Pharmaceuticals' Accounts Receivable compare to ?
Indo-Bangla Pharmaceuticals' Accounts Receivable of BDT0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Receivable for a Drug Manufacturers company?
A good Accounts Receivable depends on the Drug Manufacturers industry context. However, Accounts Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Receivable mean?
A high Accounts Receivable can signal that a stock is expensive relative to its fundamentals. Accounts receivable is the amount a company expects to receive from credit-extending customers. View historical data on Indo-Bangla Pharmaceuticals and its competitors. Indo-Bangla Pharmaceuticals's current Accounts Receivable is BDT0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indo-Bangla Pharmaceuticals stock overvalued right now?
Indo-Bangla Pharmaceuticals (DHA:IBP) has a current Accounts Receivable of BDT0.00 Mil. The current Accounts Receivable is BDT0.00 Mil. Indo-Bangla Pharmaceuticals' overall GF Score™ is 32/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Receivable calculated?
Accounts Receivable is calculated from a company's financial statements. For Indo-Bangla Pharmaceuticals (DHA:IBP), the current Accounts Receivable is BDT0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Indo-Bangla Pharmaceuticals Business Description

Comparable Companies
Address Ahmed Akbar Sobhan Road, Block B, Plot No. 183, 6th Floor, Bashundhara R/A, Baridhara, Dhaka, BGD, 1229
Indo-Bangla Pharmaceuticals Ltd is engaged in the manufacturing, marketing, and distribution of generic pharmaceutical products. The products of the company include human drugs dosages form such as tablets, capsules, syrup, oral saline, and suspension. The products of the company are sold in the domestic market.
32GF Score

Get the complete analysis for DHA:IBP

Accounts Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT19.40
Price